Revolution Medicines, Inc.
RVMD
Classement en actions
#622
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Prix de l'action
$182.91
Capitalisation boursière
$39.20B
Changement (1 jour)
2.78%
Changement (1 an)
238.10%
Pays
US
Échange Revolution Medicines, Inc. (RVMD)
Catégorie
Healthcare
EPS pour Revolution Medicines, Inc. (RVMD)
EPS au June 2026 TTM : $-8.86
Selon les derniers rapports financiers et le cours de l'action de Revolution Medicines, Inc., l’EPS actuel de la société (TTM) est de $-8.86. À la fin de 2023, la société avait un EPS de $-3.86 une augmentation par rapport à celui de 2022, qui était de $-3.08.
Historique de l'EPS de Revolution Medicines, Inc. de 2017 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-8.86 | 147.49% |
| 2024 | $-3.58 | -7.25% |
| 2023 | $-3.86 | 25.32% |
| 2022 | $-3.08 | 24.70% |
| 2021 | $-2.47 | 52.47% |
| 2020 | $-1.62 | 23.66% |
| 2019 | $-1.31 | 13.91% |
| 2018 | $-1.15 | 35.29% |
| 2017 | $-0.85 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -295.49% |
US
|
|
| $-7.98 | -9.93% |
US
|
|
| $-5.29 | -40.29% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -413.09% |
NL
|
